Line design

Olmesartan medoxomil is a popular prescription blood pressure medication marketed as Benicar®, Benicar HCT®, Azor®, or Tribenzor®. In July of 2013 the FDA issued a Safety Announcement warning that the drug can cause intestinal problems known as sprue-like enteropathy and required the manufacturer to change its label to warn of this potential injury.1

Symptoms of sprue-like enteropathy include chronic diarrhea, weight loss, nausea and vomiting.2 These symptoms can be so severe that they require hospitalization for dehydration, kidney failure, and malnourishment.3 An August 2012 Mayo Clinic study found a possible association between the drug and sprue-like enteropathy, and further found that when removed from the drug, all of the patients’ symptoms decreased, and/or resolved completely.4 Since that time, a nationwide French study was published which concluded that olmesartan “causes a severe and potentially life threatening enteropathy,” which is much more common with olmesartan than with other drugs in the same class.5

Robins Kaplan LLP has filed dozens of cases against the manufacturer in both Federal and New Jersey State Court.  In April of 2015, the federal court cases were consolidated into an MDL (multidistrict litigation) in the District of New Jersey before the Honorable Robert Kugler.6  In one of the Court’s first orders, Judge Kugler appointed Robins Kaplan partner Tara Sutton to the Plaintiff’s Executive Committee. Ms. Sutton will also Chair the Science Committee. Other Robins Kaplan members appointed to leadership positions include; Rayna Kessler, State Court Liaison; and Holly Dolejsi, Bellwether Selection Committee. Most recently, Robins Kaplan educated the Court on the scientific principles underlying this case. On May 8, 2015, Tara Sutton gave a Science Day presentation to the Judges presiding over the State and Federal Court Litigations. 

Robins Kaplan LLP continues to evaluate new Benicar cases. If you believe you or a loved one have been injured by ingesting Benicar, please contact us

Read More

1 http://www.fda.gov/Drugs/DrugSafety/ucm359477.htm
2 http://www.ncbi.nlm.nih.gov/pubmed/22728033
3 Id.
4 Id.
5 L. Marthey, G. Cadiot, et al. Olmesartan-associated Enteropathy: Results of a National Survey. Ailment. Pharmacol. Ther. (Aug. 2014).
6 http://www.jpml.uscourts.gov/sites/jpml/files/MDL-2606-Initial_Transfer-03-15.pdf

Related Attorneys

Related Services

Jump to Page

Robins Kaplan LLP Cookie Preference Center

Your Privacy

When you visit our website, we use cookies on your browser to collect information. The information collected might relate to you, your preferences, or your device, and is mostly used to make the site work as you expect it to and to provide a more personalized web experience. For more information about how we use Cookies, please see our Privacy Policy.

Strictly Necessary Cookies

Always Active

Necessary cookies enable core functionality such as security, network management, and accessibility. These cookies may only be disabled by changing your browser settings, but this may affect how the website functions.

Functional Cookies

Always Active

Some functions of the site require remembering user choices, for example your cookie preference, or keyword search highlighting. These do not store any personal information.

Form Submissions

Always Active

When submitting your data, for example on a contact form or event registration, a cookie might be used to monitor the state of your submission across pages.

Performance Cookies

Performance cookies help us improve our website by collecting and reporting information on its usage. We access and process information from these cookies at an aggregate level.

Powered by Firmseek